Quarterly ResultAug 11, 2026, 04:14 PM
Bolt Biotherapeutics Raises Going Concern Doubt; Q2 Net Loss $(7.7)M
AI Summary
Bolt Biotherapeutics, Inc. reported a net loss of $(7.7) million for the second quarter of 2026 and $(15.0) million for the first six months of 2026. The company's management has raised substantial doubt about its ability to continue as a going concern, stating that its cash and marketable securities of $18.1 million as of June 30, 2026, are not sufficient to fund operations for at least one year. The company will need to secure additional capital through partnering, equity sales, or other financing methods.
Key Highlights
- Management believes cash and marketable securities of $18.1 million are insufficient for one year, raising going concern doubt.
- Net loss for Q2 2026 was $(7.7) million, compared to $(8.6) million in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $(15.0) million, compared to $(19.6) million in H1 2025.
- Total cash, cash equivalents, and marketable securities were $18.1 million as of June 30, 2026.
- Total stockholders' equity decreased to $12.6 million from $26.5 million since December 31, 2025.
- Collaboration revenue for Q2 2026 was $5 thousand, significantly down from $1.8 million in Q2 2025.
- Net cash used in operating activities for H1 2026 was $(14.6) million, an improvement from $(23.0) million in H1 2025.
Price Impact
More from BOLT